

Neonatal Hypothyroidism

Swathi Badarla*

Montessori College of Pharmacy, Mylavaram, Vijayawada, AP, India

Review Article

Received: 27/08/2016

Revised: 29/08/2016

Accepted: 31/08/2016

*For Correspondence

Swathi B, Department of
Pharmaceutical Analysis and
Quality Assurance, Montessori
College of Pharmacy, Mylavaram,
Vijayawada, AP, India

E-mail:

swathipharmacy@52gmail.com

Keywords: Neonatal gland
disease, Newborn, Blood spot,
thyroid hormone, CH screening

ABSTRACT

Neonatal gland disease is ablated endocrine production in a very newborn. In terribly rare cases, no endocrine is made. The condition is additionally referred to as non-heritable gland disease. Non-heritable means that gift from birth. Newborn screening (NS) for non-heritable gland disease (CH) is one in all the main achievements in medicine. Most neonates born with CH have traditional look and no detectable physical signs. Gland disease within the newborn amount is nearly forever unnoted, and delayed designation results in the foremost severe outcome of CH, slowness, accentuation the importance of NS. Blood spot thyroid stimulating internal secretion (TSH) or thyroid hormone (T4) or each is used for CH screening. The latter is a lot of sensitive however not efficient, therefore screening by thyrotrophic hormone or T4 is employed in numerous programs round the world. thyrotrophic hormone screening was shown to be a lot of specific within the designation of CH. T4 screening is a lot of sensitive in police work particularly those newborns with rare hypothalamic-pituitary-hypothyroidism, however it's less specific with a high frequency of false positives chiefly in low birth weight and premature infants. Congenital gland disease (CH) happens in or so 1:2,000 to 1:4,000 newborns. The clinical manifestations area unit usually delicate or not gift at birth. This seemingly is because of trans-placental passage of some maternal endocrine, whereas several infants have some thyroid production of their own. Common symptoms embrace ablated activity and raised sleep, feeding problem, constipation, and prolonged jaundice. On examination, common signs embrace my edematous facies, massive fontanel, birth defect, a distended abdomen with herniation, and tonic. CH is assessed into permanent and transient forms, that successively is divided into primary, secondary, or peripheral etiologies. Thyroid infertility accounts for eighty fifth of permanent, primary CH, whereas inborn errors of endocrine synthesis (dys-hormonogeneses) account for 10-15% of cases. Secondary or central CH could occur with isolated thyrotrophic hormone deficiency, however a lot of ordinarily it's related to nonheritable hypopituitarism. Transient CH most ordinarily happens in preterm infants

born in areas of endemic iodine deficiency.

INTRODUCTION

Thyroid hormones play a significant role within the traditional functioning of assorted organs of the body together with neural growth, neurotransmission, neural migration and lamination accelerator induction. It's currently been established that there's an in depth association of thyroid hormones with foetal brain development. Deficiency or inadequate production of the internal secretion in neonates manifests as innate adenosis. It's typically believed to own been gift at or before birth ^[1] and has been unremarkably discovered in an exceedingly sizable amount of the themes with suspected endocrinopathies met among medicine cohort ^[2-3]. Presentation may be with multiple symptomatology, that if not evaluated early leads to Associate in Nursing irreversible, and a permanent systema nervosum injury a resulting organic process delay. This afterwards ends up in physical and mental growth retardation ^[1-20].

Nearly ten to fifteen of neonates gift with diagnostic clinical options ^[5]. At birth symptoms square measure additional evident than signs and majority of kids (about 75%) square measure diagnosed throughout the primary four to six weeks of life, ^[2] a part terribly crucial for post natal brain development. It is the most typical endocrine and most treatable reason for slowness and conjointly manifests with severe growth retardation. Thyroid hormone is crucial for traditional cerebral development within the early postnatal months; organic chemistry designation should be created presently when birth, and effective treatment initiated promptly to stop irreversible brain injury. Therefore early designation and treatment of this condition can't be over-emphasized. the appearance of babe screening programs for detection of congenital adenosis has dramatically improved the prognosis for affected infants. Early designation and adequate treatment from the primary weeks of life end in traditional linear growth and intelligence comparable that of unaffected siblings. The goal of newborn screening is to sight CH and start treatment before the babe reaches one month old-time ^[20-35].

Screening Methods

Different newborn screening programs area unit being employed in several components of the globe, every with its deserves and demerits. The out there newborn screening methods for nonheritable adenosis are:

1. Primary TSH with backup T measurements.
2. Primary T with backup TSH measurements.
3. Combined TSH and T measurements.

Epidemiology

Before the appearance of NBS programs, the incidence of CH, sometimes detected when look of clinical options, was reportable to vary between 1:7,000 and 1:10,000.4 With the NBS expertise, the incidence is taken into account as 1:3,000 to 1:4,000 live births.4 The variations in incidence square measure usually attributed to geographical and ethnic variations, however square measure a lot of possible to be

concerning iodine deficiency or style of screening technique used.⁵ a really high incidence (1:914 to 1:1,985) has been reportable from there foreme countries with not so well-established NBS programs.^{6,7} within the USA, the incidence of CH has shown a rise (from close to 1:4,100 to 1:2,350) over the past few decades.⁸ the main reason for the rise is taken into account to be the inclusion of cases with transient adenosis (TH).⁸ a standardized increase (1:3,616 in 2005, 1:1,369 in 2006, and 1:1,030 in 2007) was noted in Brazil and was chiefly attributed to reduction of infant thyroid stimulating endocrine (TSH) worth limits over time.⁹ A high incidence (1:1,800 live births) was conjointly found over a decade of usage of the NBS program in Greek Cypriot population.¹⁰ a coffee incidence of 1:10,000 (after exclusion of TH) was recorded in France when concerning a pair of decades of begin of NBS.¹¹ Thus, the malady burden continues to be high worldwide ^[36-48].

Etiology

In the majority of patients, CH is caused by Associate in Nursing abnormal development of the thyroid (thyroid dysgenesis) that is typically a spasmodic disorder and accounts for eighty fifth of cases. It presents in 3 major forms i.e. thyroid ectopy, athyreosis and thyroid dysplasia. Thyroid ectopy accounts for 2 thirds of cases of thyroid sterility and is doubly a lot of common in females. ^[49,50] the precise etiology of thyroid sterility isn't best-known. However; mutations in transcription issue genes that regulate thyroid development [thyroid transcription issue two (TTF-2), NKX2.1 (also termed TTF-1) or PAX-8] would justify these defects. But, solely two hundredth of cases with thyroid sterility are found to possess such genetic mutations. For the remaining common fraction of cases, CH results from absence of thyroid (athyrosis) and thyroid dysplasia. Hereditary inborn errors within the protein cascade of endocrine synthesis, conjointly referred to as dyshormonogenesis, or to defects in peripheral endocrine transport, metabolism, or actions are accounted in more or less V-day of cases. Defects in endocrine biogenesis are familial, typically inheritable in Associate in Nursing chromosome recessive manner. These embrace mutations within the genes writing for the sodium-iodide symporter, thyroid oxidase, oxide generation [thyroid enzyme and twin enzyme maturation factors (THOX and DUOXA)], iodinated protein (Tg) and iodoamino acid deiodinase. Defects in endocrine transport (mutations within the cistron for monocarboxylase transporter 8), metabolism (selenocysteine insertion sequence-binding macromolecule 2), or resistance to endocrine action (mutations within the endocrine receptor) are some rare causes. of those many defect, mutations in thyroid oxidase (TPO) cistron are the foremost current causes of inheritable defects in CH. ^[16] Secondary noninheritable (central) glandular disorder is also isolated which ends up from mutation in thyroid stimulating endocrine β (TSH β) fractional monetary unit cistron or TRF receptor cistron. a lot of usually it's related to non-inheritable hypopituitarism, which can ensue to mutation in transcription issue cistron regulation pituitary development i.e. HESX1, LHX4, PIT1 and PROP1. Transient CH in newborn is also thanks to maternal thyrotrophin receptor-blocking antibodies, exposure to maternal anti-thyroid medications, iodine deficiency and iodine excess ^[41-59].

Causes of Neonatal Hypothyroidism

To assess the varied causes of non-inheritable glandular disease one ought to ascertain the location of defect, whether or not it's within the thyroid, thyroid regulative system, thanks to deficient hormone

receptor activity or thanks to inborn errors of the hormone synthesis. It will be classified either as central (pituitary) glandular disease or primary glandular disease or as transient or permanent glandular disease. Majority of cases with non-inheritable glandular disease square measure infrequent in nature with only a few being thanks to inborn errors of hormone synthesis as dysghormonogenesis ^[60-73].

Causes

- Transient Primary glandular disorder
- Endemic iodine deficiency
- Prenatal and postpartum iodine excess
- Maternal TSHR obstruction antibodies
- Maternal anti-thyroid medications
- DUOX two mutation
- Isolated hyperthyrotropinemia (Normal T4, high TSH)
- Transient Secondary or tertiary glandular disorder
- Maternal glandular disease
- Prematurity, terribly low birth weight
- Drugs: monoamine neurotransmitter, steroids
- Transient Hypothyroxinemia (Low T4, traditional TSH)
- Endemic iodine deficiency
- Confirmatory bodily fluid thyroid testing ^[64-72]

Diagnostic Analysis

In countries wherever newborn screening programs surface, all infants with CH square measure diagnosed when detection by newborn screening tests. However, of the worldwide birth population of 127 million, solely twenty fifth of babies square measure invited for screening for CH. ^[17] For the remaining seventy fifth infants, significantly targeted in developing countries, clinical suspicion of hypothyroid results in thyroid perform analysis ^[73-75].

Newborn Thyroid Screening Protocols

Newborn thyroid screening tests square measure allotted before discharge from hospital, optimally between a pair of and five days older. Specimen collected before forty eight h older might cause false positive result. Screening of terribly sick newborn or when intromission might cause false negative result. In a critically unwell kid or preterm baby, or just in case of home delivery, blood sample ought to be collected by seven days older. Capillary blood samples from heel prick square measure placed on circles of specialize paper, dried at temperature, then sent to a centralized laboratory. Some programs get a routine second specimen between a pair of and week older. the extra incidence of CH supported a second screening at a pair of weeks older is just about one in thirty 000.

Earlier for screening of newborn for CH, most programs undertook AN initial T4 take a look at, followed by thyrotrophic hormone testing if the T4 worth falls beneath a discontinue limit. With increasing accuracy of

thyrotrophic hormone assays on little blood volumes, several screening programs currently have switched to AN initial thyrotrophic hormone take a look at approach to find CH. [20] every program ought to develop its own T4 and thyrotrophic hormone discontinue for take a look at result. Each strategies permit detection of the bulk of infants with CH however every approach has its own benefits and downsides. The initial T4 then follow up thyrotrophic hormone approach can find some cases of secondary or central glandular disorder and kid with "delayed thyrotrophic hormone elevation". On alternative hand initial thyrotrophic hormone approach can find delicate or subclinical types of glandular disorder. Generally, if the screening T4 worth is below the ten th mark of discontinue and/or the thyrotrophic hormone is larger than 30mU/liter (15mU/liter whole blood), AN kid ought to be recalled for confirming bodily fluid testing. In cases with "intermediate results," e.g. low T4 however thyrotrophic hormone below cutoff, a program might suggest that a repeat heel prick screening specimen be collected and sent for analysis [76-79].

Diagnosis and treatment mustn't be supported screening take a look at results alone. Neonates with abnormal thyroid screening tests ought to be recalled right away for examination and a puncture blood sample ought to be drawn for confirming bodily fluid testing. Confirming bodily fluid ought to be tested for thyrotrophic hormone and free T4, or total T4 combined with some live of binding proteins appreciate a T3 rosin uptake. (serum blood bodily fluid liquid body substance bodily fluid body fluid humor humour) thyrotrophic hormone and T4 endure dynamic changes within the initial weeks of life; it's vital to match the serum results with age-related reference values. Within the initial few days of life, bodily fluid thyrotrophic hormone will be as high as 39mU/L, due to the thyrotrophic hormone surge that's commonly seen when birth. Most confirming bodily fluid tests square measure obtained among one to 2 weeks older, once the higher thyrotrophic hormone vary has fallen to AN just about 10mU/liter. though levels of all hormones square measure higher at 1-4 days older, by 2-4 weeks older they need fallen nearer to the amount usually seen in infancy.

Formulations

Levothyroxine (l-thyroxine) is that the treatment of selection. though triiodothyronine (T3) is that the biologically active type of the internal secretion, most T3 within the brain is created from native deiodination of T4; so, T3 replacement isn't required for traditional medicine functioning. in a very study of forty seven infants given varied treatment doses of l-thyroxine, blood serum T3 traditionalized and remained normal no matter the treatment dose used, once more suggesting that treatment with l-thyroxine alone is adequate [82]. Treatment ought to be initiated in any kid with a positive screening result, right once substantiating tests area unit drawn however before results area unit out there [82,83].

Currently, solely l-thyroxine tablets area unit approved to be used within the US Thyroid suspensions ready by individual pharmacies might end in unreliable dosing. In Europe, however, l-thyroxine drops are with success used [83]. The l-thyroxine pill ought to be crushed, mixed with breast milk, formula or water and fed to the kid. The pill shouldn't be mixed with soy formula as this has been shown to interfere with absorption. One retrospective study of seventy eight patients with noninheritable adenositis showed that infants fed soy formula took considerably longer to attain a hormone beneath ten m U/l (150 days versus forty days) [84].

ought to the kid need soy formula, l-thyroxine ought to lean halfway between feeds and thyroid operate ought to be monitored fastidiously. Some biological process supplements or medicine area unit identified to interfere with absorption of l-thyroxine.

These include:

- Soy supermolecule formulas
- Focused iron
- Calcium, hydrated aluminum oxide
- Cholestyramine and alternative resins
- Fiber supplements

Dosages

The goal of medical care is to normalize T4 at intervals a pair of weeks and TSH at intervals one month. In one study infants United Nations agency took longer than a pair of weeks to normalize thyroid operate had considerably lower psychological feature, attention and accomplishment scores than people who accomplishment scores than people who achieved traditional thyroid operate at one or a pair of weeks of treatment. As Associate in Nursinging optimum medical specialty development depends on each adequacy and temporal arrangement of treatment, yankee academy of medicine and European society of medicine medical specialty suggest 10-15 $\mu\text{gm}/\text{kg}/\text{day}$ as initial dose. Studies show that this dose normalizes humor T4 at intervals three days and TSH at intervals 2-4 weeks. Initial LT4 dose and fast standardization of humor T4 ar crucial to the optimum neurodevelopmental outcome. In severe CH, it's vital to begin higher initial dose of the counseled vary to attain these goals. In one study infants United Nations agency started on higher initial doses 50 μgm had all-out IQ scores eleven points over those started on lower initial doses thirty seven.5 μgm .^[85-100].

CONCLUSION

Congenital glandular disease (CH) is one among the foremost common preventable explanation for backwardness. The most effective thanks to discover infants with CH are by screening massive populations of newborns. If the designation is created and treatment started among a number of weeks of birth, neurodevelopmental outcome usually is traditional. The etiology of the foremost common explanation for CH, thyroid infertility, is essentially unknown because the increase incidence of CH.

REFERENCES

1. Pinzon AA. Novel TSC1 Gene Mutation in a Familial Case of Tuberous Sclerosis Complex: A Case Report. J Epilepsy. 2015;1:102.
2. Henkin RI. What is an Olfactory Hallucination?. J Epilepsy. 2015;1:104.
3. Paul R and Joyce S. The Psychosocial Impact of Epilepsy; A Study on Adult People With Epilepsy Attending Clinics In Lusaka. J Epilepsy. 2015;1:101.
4. Pardo K. Neurotransmitters and Epilepsy. J Epilepsy. 2015;1:103.
5. Autism JG. Epilepsy and Mitochondrial Disease. J Ergonomics. 2015;1:102.
6. Coleman M. Epilepsy and the Autisms. J Ergonomics. 2015;1:101.

7. Ojinnaka NC. Posttraumatic Epilepsy among Epileptic Children Seen in a Pediatric Neurology Clinic in Enugu, Nigeria-A Descriptive Study. *J Epilepsy*. 2016;2:105.
8. Sokol NJ, et al. Identical Twin Discordant for Electrical Status Epilepticus of Sleep (ESES). *J Epilepsy*. 2016;2:104.
9. Rolston JD. Surgical Strategies for Epilepsy in Eloquent Areas. *J Epilepsy*. 2016;2:103.
10. Pogančev KM. Valproic Acid Induced Isolated Thrombocytopenia after Acute Respiratory Infection. *J Epilepsy*. 2016;2:106.
11. Wang J and Carroll R. Nuclear Medicine Imaging in Epilepsy. *J Epilepsy*. 2016;2:105.
12. Machado R. Understanding Hyper Motor Seizures. *J Epilepsy*. 2016;2:108.
13. Menon D, et al. Muscle-eye-brain Disease and Drug-resistant Seizures: Unravelling the Phenotypic Heterogeneity of Congenital Muscular Dystrophies. *J Epilepsy*. 2016;2:107.
14. Bonetti V. Nav1.7 Sodium Channel Isoform is Expressed in Growth Cones of Hippocampal Neurons in Culture. *J Epilepsy*. 2016; 2:106.
15. Pilla R. The Ketogenic Diet Approach as Metabolic Treatment for a Variety of Diseases. *J Epilepsy*. 2016;2:010.
16. Chentouf A. Epilepsy and Psychiatric Disorders: Is There a Common Genetic Susceptibility?. *J Epilepsy*. 2016;2:009.
17. Valencia C. Calculation of the Need of Multidisciplinary Units of Epilepsy in America. *J Epilepsy*. (2016) 2:e008. doi:10.4172/2472-0895.1000e008
18. Kar SK. Post-operative Delirium after Cardiac Surgery: Can it be Prevented?. *J Epilepsy*. 2016;2:107.
19. Chentouf A. Epilepsy and Psychiatric Disorders: Is There a Common Genetic Susceptibility?. *J Epilepsy*. 2016;2:009.
20. Pilla R. The Ketogenic Diet Approach as Metabolic Treatment for a Variety of Diseases. *J Epilepsy*. 2016;2:010.
21. Andrade-Machado R. Understanding Hyper Motor Seizures. *J Epilepsy*. 2016;2:108.
22. Nicolson TJ. Sex Differences in FDA Regulated Products: Research for the Future. *J Drug Metab Toxicol*. 2010;1:103.
23. Griffini P. Metabolites in Safety Testing: Issues and Approaches to the Safety Evaluation of Human Metabolites in a Drug that is Extensively Metabolized. *J Drug Metab Toxicol*. 2010;1:102.
24. Nicolson TJ. The Post-Transcriptional Regulator EIF2S3 and Gender Differences in the Dog: Implications for Drug Development, Drug Efficacy and Safety Profiles. *J Drug Metab Toxicol*. 2010;1:101.
25. Essawy AE. Hepatotoxicity Induced by Antifungal Drug Fluconazole in the Toads (*Bufo Regularis*). *J Drug Metab Toxicol*. 2010;1:106.

26. Uyemura K. Metabolism and Toxicity of High Doses of Cyclo (his-pro) Plus Zinc in Healthy Human Subjects. *J Drug Metab Toxicol.* 2010;1:105.
27. Grundmann O. The Gut Microbiome and Pre-systemic Metabolism: Current State and Evolving Research. *J Drug Metab Toxicol.* 2010;1:104.
28. Khargharia S. Disposition Kinetic of Amoxicillin in Healthy and Nephropathic Goats with Immunological and Residual Level in Blood and Tissues. *J Drug Metab Toxicol.* 2012;5:003.
29. Arroyo VS, et al. Liver and Cadmium Toxicity. *J Drug Metabol Toxicol.* 2012 S5:001.
30. Ebomoyi EW. Establishing Genome Sequencing Centers, the Thematic Units in the Developing Nations and the Potential Medical, Public Health and Economic Implications. *J Drug Metab Toxicol.* 2011;2:108.
31. Rudin D, et al. Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination. *J Drug Metab Toxicol.* 2011;2:107.
32. Wang C. Application of Systems Biology in Developmental Neuronal Toxicity. *J Drug Metab Toxicol.* 2011;2:101.
33. Yilmaz H and Kaya. M Acute Mixed Hepatitis Induced by Propylthiouracyl. Case Report. *J Drug Metab Toxicol.* 2011;2:111.
34. Oezguen N and Kumar S. Analysis of Cytochrome P450 Conserved Sequence Motifs between Helices E and H: Prediction of Critical Motifs and Residues in Enzyme Functions. *J Drug Metab Toxicol.* 2011;2:110.
35. Rocco DJ. Serotonin Syndrome: Opportunity for Missed Diagnosis. *J Drug Metab Toxicol.* 2011;2:109.
36. Kara B. Hyperamylasemia After Over Purchase of Clonazepam. *J Drug Metab Toxicol.* 2011; 2:113.
37. Yacob AR. Detection of Vapour Metabolites of Glue Sniffer's Urine Using Head Space Gas Chromatography Mass Spectrometry. *J Drug Metab Toxicol.* 2011;2:112.
38. Santosh Kumar. Role of Cytochrome P450 Systems in Substance of Abuse Mediated HIV-1 Pathogenesis and NeuroAIDS. *J Drug Metab Toxicol.* 2012;3:102.
39. Xin-Mei C New Progress on the Pharmacological and Pharmacokinetical Study of Ginsenoside Rg3. *J Drug Metabol Toxicol.* 2012;3:114.
40. Waring JF, et al. Gene Expression Changes Related to Synaptic Deficits in the Tg2576 Mouse Model of Alzheimer's Disease. *J Drug Metab Toxicol.* 2012;3:115.
41. Ansari R. Defining the Role of Single Nucleotide Polymorphic (SNP) in Drug Development and Toxicity. *J Drug Metab Toxicol.* 2012;3:103.
42. Colalto C. Unpredictable Adverse Reactions to Herbal Products. *J Drug Metab Toxicol.* 2012; 3:105.

43. Johnson DE. Predicting Drug Safety: Next Generation Solutions. *J Drug Metab Toxicol.* 2012; 3:106.
44. Hou SM. Susceptibility of Human Lymphocytes to 2-Nitrofluorene-Induced Gene Mutation is Strongly Dependent on Metabolic Genotypes. *J Drug Metab Toxicol.* 2012;3:116.
45. Chen Q. Vitamin C in Cancer Treatment: Where Pharmacokinetics Speaks. *J Drug Metab Toxicol.* 2012;3:107.
46. Yang L. Sex Differences in the Expression of Drug-Metabolizing and Transporter Genes in Human Liver. *J Drug Metab Toxicol.* 2012;3:119.
47. Sari A, Determination of MDA Levels in the Plant (Some *Salvia L. Taxa* Growing in Turkey). *J Drug Metab Toxicol.* 2012;3:117.
48. Akande IS. Biochemical Evaluation of Some Locally Prepared Herbal Remedies (Agbo) Currently On High Demand in Lagos Metropolis, Nigeria . *J Drug Metab Toxicol.* 2012;3:118.
49. Adebayo AJ. Influence of Isoniazid Treatment on Microsomal Lipid peroxidation and Antioxidant Defense Systems of Rats. *J Drug Metab Toxicol.* 2012;3:120.
50. Pathak A. Role of Zinc on Antioxidative Enzymes and Lipid Peroxidation in Brain of Diabetic Rats. *J Drug Metab Toxicol.* 2012;3:122.
51. Ding WX. Autophagy in Toxicology: Defense against Xenobiotics. *J Drug Metab Toxicol.* 2012; 3:108.
52. Meier-Davis SR, et al. Absorption, Distribution and Excretion Pattern of Oral and Transdermal Donepezil Hydrochloride after Single and Repeated Administration to the Rat. *J Drug Metab Toxicol.* 2012;3:123.
53. Ozok N and Celik I. Effects of Subacute and Subchronic Treatment of Synthetic Plant Growth Regulators on Liver Damage Serum Biomarkers Tissue Antioxidant Defense Systems and Lipid Peroxidation in Rats. *J Drug Metab Toxicol.* 2012;3:124.
54. Gaies E, et al. Methotrexate Side Effects: Review Article. *J Drug Metab Toxicol.* 2012;3:125.
55. Singh JK. Comparative in-vitro Intrinsic Clearance of Imipramine in Multiple Species Liver Microsomes: Human, Rat, Mouse and Dog. *J Drug Metab Toxicol.* 2012;3:126.
56. Adebayo AJ. Microsomal Lipid Peroxidation, Antioxidant Enzyme Activities in Brain of Male Rats during Long-Term Exposure to Isoniazid. *J Drug Metab Toxicol.* 2012;3:127.
57. Taguchi K, et al. A Fourteen-Day Observation and Pharmacokinetic Evaluation after a Massive Intravenous Infusion of Hemoglobin-Vesicles (Artificial Oxygen Carriers) in Cynomolgus Monkeys. *J Drug Metab Toxicol.* 2012;3:128.
58. Meier-Davis SR, et al. Comparison of Metabolism of Donepezil in Rat, Mini-Pig and Human, Following Oral and Transdermal Administration, and in an in vitro Model of Human Epidermis. *J Drug Metab Toxicol.* 2012;3:129.

59. Nahata MC. Impact of Pharmacokinetics on Dosage Requirements and Medication Safety in Pediatric Patients. *J Drug Metab Toxicol.* 2012;3:109.
60. Toffoli G. Pharmacogenetics as Innovative Approach for Phase I Clinical Studies in Cancer Patients. *J Drug Metab Toxicol.* 2012;3:110.
61. Dwivedi VK. Prevention of Cadmium Toxicity by Ceftriaxone plus Sulbactam with VRP1034 in Rats. *J Drug Metab Toxicol.* 2012;3:130.
62. Sun J. Metabolomics in Drug-induced Toxicity and Drug Metabolism. *J Drug Metab Toxicol.* 2012;3:111.
63. Bluemel J. Toxicity Testing in the 21st Century: Challenges and Perspectives. *J Drug Metab Toxicol.* 2012;3:112.
64. Iyanda AA. Assessment of Lipid Peroxidation and Activities of Antioxidant Enzymes in Phosphide- Powder Residue Exposed Rats. *J Drug Metab Toxicol.* 2012;3:132.
65. Wang C. Nonhuman Primate Models and Developmental Neuronal Toxicity. *J Drug Metab Toxicol.* 2012;3:113.
66. Johnson DE. Estimating Human Cancer Risk from Rodent Carcinogenicity Studies: The Changing Paradigm for Pharmaceuticals. *J Drug Metab Toxicol.* 2012;3:114.
67. Singh TB. Induced Acetamidiprid Toxicity in Mice: A Review. *J Drug Metab Toxicol.* 2012;3:115.
68. Singh TB. Acetamidiprid Induces Toxicity in Mice under Experimental Conditions with Prominent Effect on the Hematobiochemical Parameters. *J Drug Metab Toxicol.* 2012;3:134.
69. Sharma S. Hepatic Metabolism of 17 α -hydroxyprogesterone Caproate in Mice, Rats, Dogs, Pigs, Rabbits and Baboons: A Comparison with Human Liver Microsomes and Human Hepatocytes. *J Drug Metab Toxicol.* 2012;3:135.
70. Cavallaro S. Transcriptional Mechanisms Underlying Apoptosis in Cerebellar Granule Neurons. *J Drug Metab Toxicol.* 2012;3:136.
71. Mckenzieim JM and ZAKARIJA. Fetal and Neonatal Hyperthyroidism and Hypothyroidism due to Maternal TSH Receptor Antibodies. *Thyroid.* 2009;2:155-159.
72. Tillotson S L. Relation between biochemical severity and intelligence in early treated congenital hypothyroidism: a threshold effect. *BMJ.* 1994;309:440.
73. Delange F. Neonatal Screening for Congenital Hypothyroidism: Results and Perspectives. *HORNONES. N Engl J Med.* 1997;48:51-61.
74. Engl NJ. Familial Neonatal Transient Hypothyroidism Due to Maternal TSH-Binding Inhibitor Immunoglobulins. *N Engl J Med.* 1980;303:738-741.
75. D Bunick. Developmental expression of testis messenger ribonucleic acids in the rat following propylthiouracil-induced neonatal hypothyroidism. *Biolreprod.* 1994;51:706-713.
76. Vigneri R. Subclinical Hypothyroidism in Early Childhood: A Frequent Outcome of Transient Neonatal Hyperthyrotropinemia. *Biolreprod.* 2011;51:706-713.

77. Senée V. Mutations in *GLIS3* are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism. *Thyroid*. 2006;38:682-687.
78. Nishiyama S, et al. Transient Hypothyroidism or Persistent Hyperthyrotropinemia in Neonates Born to Mothers with Excessive Iodine Intake. *Thyroid*. 2005;14:1077-1083.
79. VAN VLIET G. Neonatal Hypothyroidism: Treatment and Outcome. *Thyroid*. 2009;9:79-84.
80. Hrytsiuk I. Starting Dose of Levothyroxine for the Treatment of Congenital Hypothyroidism. *Arch Pediatr Adolesc Med*. 2002;156:485-491.
81. Engl NJ Med. Deletion of Thyroid Transcription Factor-1 Gene in an Infant with Neonatal Thyroid Dysfunction and Respiratory Failure. 1998;338:1317-1318.
82. Bartalen L. Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. *J Endocrinol Invest*. 2001;24:116–130.
83. Glinoe D and Delange F. The Potential Repercussions of Maternal, Fetal, and Neonatal Hypothyroxinemia on the Progeny. *Thyroid*. 2009;10:871-887.
84. Peleg. The Relationship Between Maternal Serum Thyroid-Stimulating Immunoglobulin and Fetal and Neonatal Thyrotoxicosis. *Obstetrics & Gynecology*. 2002;99:1040-1043.
85. George W. Thyroid Dysfunction in Pregnancy - Fetal Loss and Follow-up Evaluation of Surviving Infants. *N Engl J Med*. 1962;267:426-431.
86. Fetal DZ. Neonatal Hyperthyroidism. *Thyroid*. 2009;9:727-733.
87. DELANGE F. Screening for Congenital Hypothyroidism Used as an Indicator of the Degree of Iodine Deficiency and of its Control. *Thyroid*. (2009);8:1185-1192.
88. Bunick D. Developmental expression of testis messenger ribonucleic acids in the rat following propylthiouracil-induced neonatal hypothyroidism. *Biolreprod*. 1994;51:706-713.
89. Longnecker A. Polychlorinated Biphenyl (PCB) Exposure in Relation to Thyroid Hormone Levels in Neonates. *Thyroid*. 2000;11:249-254.
90. Stephen Lafranchi. Congenital Hypothyroidism: Etiologies, Diagnosis, and Management. *Thyroid*. 2009;9:735-740.
91. Macchia EP. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. *Nat Genet*. 1998;19:83-86.
92. Grüter A and Krude H. Detection and treatment of congenital hypothyroidism. *Nature Reviews Endocrinology*. 2012;8:104-113.
93. Téllez TR. Long-Term Environmental Exposure to Perchlorate Through Drinking Water and Thyroid Function During Pregnancy and the Neonatal Period. *Thyroid*. 2005;15:963-975.
94. Rastogi MV and LaFranchi SH. Congenital hypothyroidism. *BioMed Cent*. 2010;5:17.
95. Rovet J and Daneman D. Congenital Hypothyroidism. *D. Pediatr-Drugs*. 2003;5:141.
96. Grasberger H and Refetoff S. Genetic causes of congenital hypothyroidism due to dysmorphogenesis. *Curr Opin Pediatr*. 2011;23:421-428.

97. Patel MS. Influence of neonatal hypothyroidism on the development of ketone-body-metabolizing enzymes in rat brain. *Biochemical Jour.* 1979;184:169-172.
98. Bickel H. Schönberg Neonatal mass screening for metabolic disorders. *Eur J Pediatr.* 1981; 137:133.
99. Lafranchi S. Function in the Preterm Infant. *Thyroid.* 2009;71-78.
100. Herbstman, et al. Birth Delivery Mode Modifies the Associations between Prenatal Polychlorinated Biphenyl (PCB) and Polybrominated Diphenyl Ether (PBDE) and Neonatal Thyroid Hormone Levels. *Environmental Health Perspectives.* 2008;116:1376-82.